Participants

Thank you to each MAVRIC-IPF participant. Your participation will help us learn valuable information that might help the IPF community.

Our study goal is to enroll approximately 800 participants. Of these approximately 400 will be randomized to receive either Metformin or placebo based on the following criteria:

• Age 40 or over
• Diagnosed with IPF
• Have a certain protein signature on a research blood test
• Other enrollment criteria apply

We are using a research test called a protein signature as one of the criteria for determining who is eligible to be randomized to receive either metformin or placebo in this study. The presence of this signature may be linked to certain health outcomes, and this is another thing we want to learn as part of this study.  

Importantly, if you are taking FDA-approved treatment for your IPF, you still may be eligible to enroll in this study. 

Researchers will follow study participants for up to two years.

Participation includes a mix of in-person clinic visits and remote telephone follow-up visits. There is an initial screening visit to determine participation eligibility. The screening visit is followed by an enrollment visit where eligible participants are randomized to receive Metformin or the inactive placebo medication.

Study participants will be asked to give samples of blood, stool, and oral swabs. Lung function testing, commonly performed as part of routine clinical care, will be measured several times throughout the study. This will help researchers understand more about how Metformin works when taken by those living with IPF.

The most important aspect is participant safety. The study coordinator will explain the risks of study participation to you. Safety-related medical testing will be completed many times during participation.